CN105873935B - 结晶的β-内酰胺酶抑配制品 - Google Patents

结晶的β-内酰胺酶抑配制品 Download PDF

Info

Publication number
CN105873935B
CN105873935B CN201480071497.4A CN201480071497A CN105873935B CN 105873935 B CN105873935 B CN 105873935B CN 201480071497 A CN201480071497 A CN 201480071497A CN 105873935 B CN105873935 B CN 105873935B
Authority
CN
China
Prior art keywords
methyl
formula
heptane
dioxide
ium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480071497.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN105873935A (zh
Inventor
亚历山德罗·拉莫尼卡
马尔科·福尔扎蒂
斯特凡诺·比翁迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aoqide Pharmaceutical Co.,Ltd.
Original Assignee
Archer Daniels Midland Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49818360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105873935(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Archer Daniels Midland Co filed Critical Archer Daniels Midland Co
Publication of CN105873935A publication Critical patent/CN105873935A/zh
Application granted granted Critical
Publication of CN105873935B publication Critical patent/CN105873935B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/86—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with only atoms other than nitrogen atoms directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/87—Compounds being unsubstituted in position 3 or with substituents other than only two methyl radicals attached in position 3, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480071497.4A 2013-11-08 2014-11-07 结晶的β-内酰胺酶抑配制品 Active CN105873935B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1319776.9A GB201319776D0 (en) 2013-11-08 2013-11-08 Compound
GB1319776.9 2013-11-08
GBGB1408643.3A GB201408643D0 (en) 2013-11-08 2014-05-15 Compound
GB1408643.3 2014-05-15
PCT/EP2014/074108 WO2015067787A1 (en) 2013-11-08 2014-11-07 Crystalline beta-lactamase inhibitor

Publications (2)

Publication Number Publication Date
CN105873935A CN105873935A (zh) 2016-08-17
CN105873935B true CN105873935B (zh) 2019-03-19

Family

ID=49818360

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480071497.4A Active CN105873935B (zh) 2013-11-08 2014-11-07 结晶的β-内酰胺酶抑配制品

Country Status (14)

Country Link
US (2) US20160289245A1 (enExample)
EP (1) EP3066103A1 (enExample)
JP (2) JP7045795B2 (enExample)
KR (1) KR20160081964A (enExample)
CN (1) CN105873935B (enExample)
AU (1) AU2014345507B2 (enExample)
CA (1) CA2929199C (enExample)
CL (1) CL2016001097A1 (enExample)
EA (1) EA031348B1 (enExample)
GB (2) GB201319776D0 (enExample)
IL (1) IL245386A0 (enExample)
MX (1) MX2016005869A (enExample)
PE (1) PE20160890A1 (enExample)
WO (1) WO2015067787A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201319776D0 (en) * 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound
WO2026086730A1 (zh) * 2024-10-21 2026-04-30 齐鲁制药有限公司 恩美他唑巴坦的晶型及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070705A1 (en) * 2003-08-21 2005-03-31 Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of 3-methylcepham derivatives
US20050228176A1 (en) * 2004-04-07 2005-10-13 Orchid Chemicals And Pharmaceuticals Ltd. Process for the preparation of tazobactam in pure form
WO2008010048A2 (en) * 2006-07-12 2008-01-24 Orchid Chemicals & Pharmaceuticals Limited Novel 2-substituted methyl penam derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562073A (en) * 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
US6156745A (en) * 1997-12-29 2000-12-05 Research Corporation Technologies, Inc. 2β-substituted-6-alkylidene penicillanic acid derivatives as β-lactamase inhibitors
NZ610247A (en) * 2010-11-25 2014-09-26 Allecra Therapeutics Gmbh Β-lactamase inhibitors and their use
EP2847205A4 (en) * 2012-05-07 2016-01-20 Univ California NOVEL OXYSTEROL ANALOGUE OXY149 FOR THE INDUCTION OF OSTEOGENESIS AND HEDGEHOG SIGNAL PATH AND THE INHIBITION OF ADIPOGENESIS
US9683009B2 (en) * 2013-05-02 2017-06-20 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
GB201319776D0 (en) 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound
GB201408649D0 (en) * 2014-05-15 2014-07-02 Allecra Therapeutics Sas Method
KR20170101940A (ko) * 2014-12-09 2017-09-06 워쏘우 오르쏘페딕 인코포레이티드 스테롤 관련 화합물 및 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070705A1 (en) * 2003-08-21 2005-03-31 Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of 3-methylcepham derivatives
US20050228176A1 (en) * 2004-04-07 2005-10-13 Orchid Chemicals And Pharmaceuticals Ltd. Process for the preparation of tazobactam in pure form
WO2008010048A2 (en) * 2006-07-12 2008-01-24 Orchid Chemicals & Pharmaceuticals Limited Novel 2-substituted methyl penam derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Amorphous pharmaceutical solids: preparation, characterization and stabilization;Lian Yu，等;《Advanced Drug Delivery Reviews》;20010516;第48卷(第1期);第27-42页 *

Also Published As

Publication number Publication date
EP3066103A1 (en) 2016-09-14
GB201319776D0 (en) 2013-12-25
CA2929199A1 (en) 2015-05-14
GB201408643D0 (en) 2014-07-02
US20190071456A1 (en) 2019-03-07
JP7045795B2 (ja) 2022-04-01
CA2929199C (en) 2023-01-03
CL2016001097A1 (es) 2016-12-02
AU2014345507A1 (en) 2016-05-19
WO2015067787A1 (en) 2015-05-14
JP2016535054A (ja) 2016-11-10
US20160289245A1 (en) 2016-10-06
AU2014345507B2 (en) 2018-11-22
JP2021102642A (ja) 2021-07-15
EA031348B1 (ru) 2018-12-28
JP7346485B2 (ja) 2023-09-19
KR20160081964A (ko) 2016-07-08
PE20160890A1 (es) 2016-08-25
CN105873935A (zh) 2016-08-17
MX2016005869A (es) 2017-01-05
US11124526B2 (en) 2021-09-21
IL245386A0 (en) 2016-06-30
EA201690963A1 (ru) 2016-10-31

Similar Documents

Publication Publication Date Title
US9283210B2 (en) Amorphous mirabegron and processes for crystal forms of mirabegron
EP1310502B1 (en) Phosphonocephem compound
RU2467012C2 (ru) Способ очистки стауроспорина и способ получения n-бензоилстауроспорина
US20160272627A1 (en) Polymorphic forms of suvoroxant
JP2020530473A (ja) ロキサデュスタットの多形および共結晶
WO2018148961A1 (zh) Acp-196盐的晶型、其制备方法、药物组合物和用途
US20190282546A1 (en) Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof
WO2015104658A2 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
WO2016027243A1 (en) Novel solid state forms of afatinib dimaleate
JP7346485B2 (ja) 結晶性β－ラクタマーゼ阻害剤
US20140005381A1 (en) Novel process for refining cefmetazole sodium
WO2020049598A2 (en) Apalutamide polymorphs
CA2460970C (en) Processes for preparing crystalline and amorphous mupirocin calcium
EP1373276A1 (en) Process for the preparation of cefpodoxime proxetil
US8871927B2 (en) Method for purifying Ceftizoxime sodium
EP3240575A1 (en) Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib
BR112016010282B1 (pt) Composição farmacêutica compreendendo um inibidor de betalactamase cristalino
EP3231806B1 (en) Methods for preparing penams
ZA200402276B (en) Process for preparing crystalline and amorphous mupirocin calcium.
KR20100098439A (ko) β-락탐 화합물의 안정형 결정

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20260327

Address after: India

Patentee after: Aoqide Pharmaceutical Co.,Ltd.

Country or region after: India

Address before: Saint Louis France

Patentee before: ALLECRA THERAPEUTICS S.A.S.

Country or region before: France

TR01 Transfer of patent right